


WHAT IS CLAIMED IS:

1. A compound comprising a plurality of covalently-bound 2'-modified nucleosides having the formula:



5 wherein:

each B is a nucleobase;

one of X_1 or X_2 is O, and the other of X_1 or X_2 is S;

each R_1 is, independently, H, hydroxyl, C_1 - C_{20} alkyl, C_3 - C_{20} alkenyl, C_2 - C_{20} alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-

phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;

or R_1 is a group of formula $Z-R_{22}-(R_{23})_v$;


Z is O, S, NH, or $N-R_{22}-(R_{23})_v$;

R_{22} is C_1-C_{20} alkyl, C_2-C_{20} alkenyl, or C_2-C_{20} alkynyl;

R_{23} is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

v is from 0 to about 10;

or R_1 has the formula:



y_1 is 0 or 1;

y_2 is independently 0 to 10;


y_3 is 1 to 10;

E is C_1-C_{10} alkyl, $N(Q_1)(Q_2)$ or $N=C(Q_1)(Q_2)$;


each Q_1 and Q_2 is, independently, H, C_1 - C_{10} alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support; or Q_1 and Q_2 , together, are
 5 joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;

or R_1 has one of formula I or II:

10



I



II

wherein

Z_0 is O, S, or NH;

q^1 is from 0 to 10;

q^2 is from 1 to 10;

q^3 is 0 or 1;

q^4 is, 0, 1 or 2;

Z_4 is OM_1 , SM_1 , or $N(M_1)_2$;

each M_1 is, independently, H, C_1 - C_8 alkyl, C_1 - C_8
 20 haloalkyl, $C(=NH)N(H)M_2$, $C(=O)N(H)M_2$ or $OC(=O)N(H)M_2$;

M_2 is H or C_1 - C_8 alkyl;

Z_1 , Z_2 and Z_3 comprise a ring system having from
 about 4 to about 7 carbon atoms, or having from about 3 to
 about 6 carbon atoms and 1 or 2 hetero atoms wherein said
 25 hetero atoms are selected from oxygen, nitrogen and sulfur,
 and wherein said ring system is aliphatic, unsaturated
 aliphatic, aromatic, or saturated or unsaturated
 heterocyclic; and

Z₅ is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, N(Q₁)(Q₂), OQ₁, halo, SQ₁ or CN;

5 n is from 2 to 50; and

m is 0 or 1.

2. The compound of claim 1 wherein R₁ is -O-CH₂-CH₂-O-CH₃.


3. The compound of claim 1 wherein n is about 5 to 10 about 50.

4. The compound of claim 1 wherein n is about 8 to about 30.

5. The compound of claim 1 wherein n is about 4 to about 15.

15 6. The compound of claim 1 wherein n is 2 to about
10.

~~7.~~ An oligonucleotide having the Formula:



wherein:

each B is a nucleobase;

X_1 is S;

5 X_2 is O;

each R_1 , is, independently, H, hydroxyl, C_1 - C_{20} alkyl, C_3 - C_{20} alkenyl, C_2 - C_{20} alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter

10

molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;

or R_1 is a group of formula $Z-R_{22}-(R_{23})_v$;


Z is O, S, NH, or $N-R_{22}-(R_{23})_v$;

5 R_{22} is C_1-C_{20} alkyl, C_2-C_{20} alkenyl, or C_2-C_{20} alkynyl;

R_{23} is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, 15 polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

v is from 0 to about 10;

20 or R_1 has the formula:



y_1 is 0 or 1;

y_2 is independently 0 to 10;

y_3 is 1 to 10;

25 E is C_1-C_{10} alkyl, $N(Q_1)(Q_2)$ or $N=C(Q_1)(Q_2)$;


each Q_1 and Q_2 is, independently, H, C_1-C_{10} alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group,

T04260" TEE9660


a linker to a solid support; or Q_1 and Q_2 , together, are joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;

5

or R_1 has one of formula I or II:



I



II

wherein

10

Z_0 is O, S, or NH;

q^1 is from 0 to 10;

q^2 is from 1 to 10;

q^3 is 0 or 1;

q^4 is, 0, 1 or 2;

15

Z_4 is OM_1 , SM_1 , or $N(M_1)_2$;

each M_1 is, independently, H, C_1 - C_8 alkyl, C_1 - C_8 haloalkyl, $C(=NH)N(H)M_2$, $C(=O)N(H)M_2$ or $OC(=O)N(H)M_2$;

M_2 is H or C_1 - C_8 alkyl;

Z_1 , Z_2 and Z_3 comprise a ring system having from about 4 to about 7 carbon atoms, or having from about 3 to about 6 carbon atoms and 1 or 2 hetero atoms wherein said hetero atoms are selected from oxygen, nitrogen and sulfur, and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic; and

25

Z_5 is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms,

alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, $N(Q_1)(Q_2)$, OQ_1 , halo, SQ_1 or CN;

n is from 2 to 50; and

m is 0 or 1;

5 R_2 is H, a hydroxyl protecting group, or an oligonucleotide; and

R_3 is OH, an oligonucleotide, or a linker connected to a solid support.

8. The compound of claim 7 wherein R_1 is $-O-CH_2-CH_2-O-$
10 CH_3 .


9. The compound of claim 8 wherein R_2 is H, and R_3 is OH.

10. The compound of claim 8 wherein R_2 is a phosphodiester-linked oligonucleotide or a phosphorothioate
15 linked oligonucleotide.

11. The compound of claim 8 R_3 is a phosphodiester-linked oligonucleotide or a phosphorothioate linked oligonucleotide.

~~12.~~ R_2 and R_3 are each a phosphodiester-linked
20 oligonucleotide or a phosphorothioate linked oligonucleotide.

~~13.~~ A compound having the Formula:



wherein:

25 W^1 has the Formula:

each B is a nucleobase;
one of X₁ or X₂ is O, and the other of X₁ or X₂ is S;
5 each R₁, is, independently, H, hydroxyl, C₁-C₂₀ alkyl, C₃-C₂₀ alkenyl, C₂-C₂₀ alkynyl, halogen, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-

phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, or polyether;

or R_1 is a group of formula $Z-R_{22}-(R_{23})_v$;


Z is O, S, NH, or $N-R_{22}-(R_{23})_v$;

R_{22} is C_1-C_{20} alkyl, C_2-C_{20} alkenyl, or C_2-C_{20} alkynyl;

R_{23} is hydrogen, amino, halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides;

v is from 0 to about 10;

or R_1 has the formula:



25

y_1 is 0 or 1;

y_2 is independently 0 to 10;


y_3 is 1 to 10;

E is C_1-C_{10} alkyl, $N(Q_1)(Q_2)$ or $N=C(Q_1)(Q_2)$;


each Q_1 and Q_2 is, independently, H, C_1 - C_{10} alkyl, substituted alkyl, dialkylaminoalkyl, a nitrogen protecting group, a tethered or untethered conjugate group, a linker to a solid support; or Q_1 and Q_2 , together, are
 5 joined in a nitrogen protecting group or a ring structure that can include at least one additional heteroatom selected from N and O;

or R_1 has one of formula I or II:

10



I



II

wherein

- Z_0 is O, S, or NH;
- q^1 is from 0 to 10;
- q^2 is from 1 to 10;
- q^3 is 0 or 1;
- q^4 is, 0, 1 or 2;
- Z_4 is OM_1 , SM_1 , or $N(M_1)_2$;
- each M_1 is, independently, H, C_1 - C_8 alkyl, C_1 - C_8
 20 haloalkyl, $C(=NH)N(H)M_2$, $C(=O)N(H)M_2$ or $OC(=O)N(H)M_2$;
- M_2 is H or C_1 - C_8 alkyl;

Z_1 , Z_2 and Z_3 comprise a ring system having from about 4 to about 7 carbon atoms, or having from about 3 to about 6 carbon atoms and 1 or 2 hetero atoms wherein said
 25 hetero atoms are selected from oxygen, nitrogen and sulfur, and wherein said ring system is aliphatic, unsaturated aliphatic, aromatic, or saturated or unsaturated heterocyclic; and


Z₅ is alkyl or haloalkyl having 1 to about 10 carbon atoms, alkenyl having 2 to about 10 carbon atoms, alkynyl having 2 to about 10 carbon atoms, aryl having 6 to about 14 carbon atoms, N(Q₁)(Q₂), OQ₁, halo, SQ₁ or CN;

5 n is from 2 to 50; and

```
m is 0 or 1;
```

R₂ is H, a hydroxyl protecting group, or an oligonucleotide;

W^3 has the Formula:



wherein R_3 is OH, an oligonucleotide, or a linker connected to a solid support; and

W^2 is a plurality of covalently bound nucleosides linked by phosphodiester or phosphorothioate linkages.

5 14. The compound of claim 13 wherein R_1 is $-O-CH_2-CH_2-O-CH_3$.

15 15. The compound of claim 14 wherein R_2 is H, and R_3 is OH.

10 16. The compound of claim 14 wherein n is about 5 to about 50.

15 17. The compound of claim 14 wherein n is about 8 to about 30.

15 18. The compound of claim 14 wherein n is about 4 to about 15.

15 19. The compound of claim 14 wherein n is 2 to about 10.

20 20. The compound of claim 14 wherein W^2 is a plurality of covalently bound nucleosides linked by phosphodiester linkages.

20 21. The compound of claim 14 wherein W^2 is a plurality of covalently bound nucleosides linked by phosphorothioate linkages.

25 22. A composition comprising a compound of claim 1 and an acceptable carrier.

23. A composition comprising a compound of claim 7 and an acceptable carrier.

24. A composition comprising a compound of claim 12 and an acceptable carrier.

5 25. A method of modulating the production or activity of a protein in an organism, comprising contacting said organism with a compound of claim 1.

26. A method of modulating the production or activity of a protein in an organism, comprising contacting said
10 organism with a compound of claim 7.

27. A method of modulating the production or activity of a protein in an organism, comprising contacting said organism with a compound of claim 13.

15 28. A method of treating an organism having a disease characterized by the undesired production of a protein, contacting said organism with a compound of claim 1.

*SUB
AS*
20 29. A method of treating an organism having a disease characterized by the undesired production of a protein, contacting said organism with a compound of claim 7.

30. A method of treating an organism having a disease characterized by the undesired production of a protein, contacting said organism with a compound of claim 13.

25 31. A method of assaying a nucleic acid, comprising contacting a solution suspected to contain said nucleic acid with a compound of claim 1.

006551.09701
T07260" T559660

32. A method of assaying a nucleic acid, comprising contacting a solution suspected to contain said nucleic acid with a compound of claim 7.

33. A method of assaying a nucleic acid, comprising
5 contacting a solution suspected to contain said nucleic acid
with a compound of claim 13.

Add A^6